Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Bertè
R
R
Department of Internal Medicine, Hematology and Oncology Program, Hospital of Piacenza, Italy.
Vallisa
D
D
Civardi
G
G
Moroni
C F
CF
Lazzaro
A
A
Cavanna
L
L
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D016898:Interferon-alpha; D003561:Cytarabine; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate